Replimune Group (FRA:7R8) EBITDA Margin %: 0.00% (As of Mar. 2026)


FRA:7R8 Replimune Group Inc FRA:7R8
32 GF Score
Price €9.22
! 4 Warning Signs
View Full Analysis

What is Replimune Group EBITDA Margin %?

Replimune Group FRA:7R8 -3.56% 32 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates FRA:7R8 with a GF Score™ of 32/100. The stock has 4 warning signs investors should review. Among 937 Biotechnology companies, Replimune Group ranks worse than 106723.48% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Replimune Group's EBITDA for the three months ended in Mar. 2026 was €-60.39 Mil. Replimune Group's Revenue for the three months ended in Mar. 2026 was €0.00 Mil. Therefore, Replimune Group's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.

Replimune Group  (FRA:7R8) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Replimune Group EBITDA Margin % Related Terms

Replimune Group EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Replimune Group's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Replimune Group EBITDA Margin % Chart

Replimune Group Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Replimune Group Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FRA:7R8 vs AVTX, KURA, SANA: EBITDA Margin % Comparison

For the Biotechnology subindustry, Replimune Group's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Replimune Group EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Replimune Group's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Replimune Group's EBITDA Margin % falls into.


FRA:7R8
32GF Score
Replimune Group Inc FRA:7R8
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Replimune Group EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Replimune Group's EBITDA Margin % for the fiscal year that ended in Mar. 2026 is calculated as

EBITDA Margin %=EBITDA (A: Mar. 2026 )/Revenue (A: Mar. 2026 )
=-261.489/0
= %

Replimune Group's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-60.387/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Replimune Group (FRA:7R8) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Replimune Group and its competitors. According to the industry distribution chart, Replimune Group ranks #999999 out of 937 companies in the Biotechnology industry.
Is Replimune Group's EBITDA Margin % too high?
Replimune Group's current EBITDA Margin % is 0.00%. Based on the distribution chart, Replimune Group ranks #999999 out of 937 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Replimune Group has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Replimune Group's EBITDA Margin % compare to AVTX and KURA?
According to the Biotechnology industry distribution chart, Replimune Group ranks #999999 out of 937 companies for EBITDA Margin %. This places Replimune Group in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Replimune Group and its competitors. Replimune Group's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Replimune Group stock overvalued right now?
Replimune Group (FRA:7R8) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Replimune Group's overall GF Score™ is 32/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Replimune Group (FRA:7R8), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Replimune Group Business Description

Other Exchanges REPL:USA
Address 500 Unicorn Park Drive, Suite 303, 3rd Floor, Woburn, MA, USA, 01801
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
32GF Score

Get the complete analysis for FRA:7R8

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€9.22
Price